Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Story1
Eli Lilly discloses 5,480,872-share stake in TRex Bio after IPO allocation
A Schedule 13D filed by Eli Lilly and Company on 16 October 2026 shows the drugmaker holds 5,480,872 shares of TRex Bio, Inc., built from preferred-stock conversions and an IPO purchase, with a Lilly employee sitting on TRex Bio's board.
Company or person1
ELI LILLY & Co
Company
Primary record20
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-11-04.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-11-03.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-11-03.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-11-03.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-11-03.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-11-03.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-11-03.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-11-03.
ELI LILLY & Co filed 8-K
Item 2.02. Results of Operations and Financial Condition. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of th
FEDEX CORP filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 26, 2026, FedEx Corporation (“FedEx” or “the Compan
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-10-20.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-10-20.
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-10-20.
ELI LILLY & Co filed SCHEDULE 13G/A
0000316011-26-000036.txt : 20261019 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0000911916-94-000024 0000316011 XXXXXXXX LIVE 47 Common Stock, Without Par Value 09/30/2026 0000059478 ELI LILLY AND COMPANY 53245
ELI LILLY & Co filed SCHEDULE 13D
pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended, on October 9, 2026. Common Stock, par value $0.0001 per share TRex Bio, Inc. C/O TREX BIO, INC. 269 EAST GRAND AVENUE SUITE 300 SOUTH SAN FRANCISCO CA
Aardvark Therapeutics, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2026, the board of directors (the Board ) of Aard
Foghorn Therapeutics Inc. filed 8-K
Item 2.05 Costs Associated with Exit or Disposal Activities. On September 25, 2026, following review of clinical data from the Phase 1 trial of FHD-909, Foghorn Therapeutics Inc. (the Company ) and Eli Lilly and Company
Altimmune, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, the Board of Directors (the Board ) of A
NEKTAR THERAPEUTICS filed 8-K
Item 8.01 Other Events. In August 2023, Nektar Therapeutics (the Company ) filed a complaint in the U.S. District Court for the Northern District of California (the District Court ) against Eli Lilly and Company ( Lilly
ELI LILLY & Co filed 4
SEC form 4 filed by ELI LILLY & Co (CIK 59478) on 2026-09-22.